Two debuting biotechs used IPOs to put fresh capital behind late-stage ambitions and targeted discovery programs. Latigo Biotherapeutics raised $346 million for a pipeline that includes a next-generation non-opioid pain drug expected to be ready for pivotal testing, while BlossomHill Therapeutics also debuted on Nasdaq to pursue cancer drugs aimed at mutations not covered by existing therapies. The report frames the cash as runway for clinical advancement and broader platform development. For investors and peers, IPO activity can also indicate market appetite for differentiated mechanisms in pain and mutation-driven oncology. Separately, the capital inflow may strengthen competition in mechanism-of-action niches where differentiation is hard but patient need is high.